glp-1 manufacturing The boom: Challenges, trends, and CapEx strategies for manufacturers Scaling for the GLP-1 revolution
Description
2024;109(3):e126779
The candidate, ribupatide, also called KAI-9531, works by targeting the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, thereby mimicking the hormones that regulate appetite in the brain and intestines just like Zepbound
2021;5(6):e133429
doi: 10.1111/dom.12985
_1755853304_WNo_587d407.webp)
Patients report benefits like weight loss (1525% of body weight), reduced cravings, and better hormonal balance
Is It the Flu or the Ozempic Flu
